Christina Cooley

Title: Christina Cooley: Innovator in Therapeutic Compounds

Introduction

Christina Cooley is a prominent inventor based in San Antonio, TX (US). She has made significant contributions to the field of therapeutic compounds, holding two patents that focus on enhancing the unfolded protein response (UPR) in cells. Her work aims to address critical health issues related to proteostasis and various diseases.

Latest Patents

Christina Cooley's latest patents include innovative compounds designed to selectively activate the inositol-requiring enzyme 1 (IRE1)/X-box binding protein 1 (XBP1s) signaling pathway. These compounds are particularly useful in treating diseases characterized by imbalances in proteostasis within the endoplasmic reticulum (ER) or secretory pathway. Notably, her inventions do not target the IRE1 kinase domain, making them unique in their therapeutic approach. Additionally, she has developed compounds that activate the activating transcription factor 6 (ATF6) arm of the UPR. These compounds are intended for the treatment of conditions involving folding disorders, such as lysosomal storage diseases and antitrypsin-associated emphysema. They are also expected to have beneficial effects in managing Alzheimer's disease and diabetes.

Career Highlights

Christina Cooley is affiliated with The Scripps Research Institute, where she continues her research and development of therapeutic compounds. Her work has garnered attention for its potential to improve treatment options for various diseases linked to protein misfolding and cellular stress.

Collaborations

Some of Christina's notable coworkers include R Luke Wiseman and Jeffery W Kelly, who contribute to her research endeavors and the advancement of her innovative projects.

Conclusion

Christina Cooley's contributions to the field of therapeutic compounds highlight her role as a leading inventor in addressing complex health challenges. Her patents reflect a commitment to advancing medical science and improving patient outcomes.